# A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies

> **NCT06628687** · — · RECRUITING · sponsor: **Biogen** · enrollment: 20 (estimated)

## Conditions studied

- Friedreich Ataxia

## Interventions

- **DRUG:** Omaveloxolone

## Key facts

- **NCT ID:** NCT06628687
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-26
- **Primary completion:** 2035-04-30
- **Final completion:** 2035-04-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06628687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06628687, "A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT06628687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*